The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis

被引:31
|
作者
Schweitzer, Nora [1 ]
Weber, Tim [1 ]
Kirstein, Martha M. [1 ]
Fischer, Mareike [1 ,2 ]
Kratzel, Anna-Maria [1 ]
Reineke-Plaass, Tanja [3 ]
Lehner, Frank [4 ]
Manns, Michael P. [1 ]
Vogel, Arndt [1 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Klinikum Hildesheim, Dept Cardiol Angiol & Intens Care, Senator Braun Allee 33, D-31135 Hildesheim, Germany
[3] Hannover Med Sch, Dept Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[4] Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Cholangiocarcinoma; CCA; Intrahepatic; ICC; Survival; Adjuvant chemotherapy; PROGNOSTIC-FACTORS; SURGICAL-TREATMENT; MORTALITY-RATES; UNITED-STATES; TRENDS; SURVIVAL; BILIARY; EXPERIENCE; INCREASE; CANCER;
D O I
10.1007/s00432-017-2392-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT). Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors. Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients. We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.
引用
收藏
页码:1347 / 1355
页数:9
相关论文
共 50 条
  • [1] The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis
    Nora Schweitzer
    Tim Weber
    Martha M. Kirstein
    Mareike Fischer
    Anna-Maria Kratzel
    Tanja Reineke-Plaaß
    Frank Lehner
    Michael P. Manns
    Arndt Vogel
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1347 - 1355
  • [2] Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis
    Reames, Bradley N.
    Bagante, Fabio
    Ejaz, Aslam
    Spolverato, Gaya
    Ruzzenente, Andrea
    Weiss, Matthew
    Alexandrescu, Sorin
    Marques, Hugo P.
    Aldrighetti, Luca
    Maithel, Shishir K.
    Pulitano, Carlo
    Bauer, Todd W.
    Shen, Feng
    Poultsides, George A.
    Soubrane, Oliver
    Martel, Guillaume
    Koerkamp, Bas G.
    Guglielmi, Alfredo
    Itaru, Endo
    Pawlik, Timothy M.
    HPB, 2017, 19 (10) : 901 - 909
  • [3] The Role of Adjuvant Chemotherapy and Radiation in Resected Intrahepatic Cholangiocarcinoma
    Ankeny, J. S.
    Marmor, S.
    Akers, M. J.
    LaRocca, C. J.
    Hui, J. Y.
    Tuttle, T. M.
    Jensen, E. H.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S99 - S100
  • [4] Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
    Yadav, S.
    Xie, H.
    Riaz, I. B.
    Sharma, P.
    Mahipal, A.
    McWilliams, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
    Yadav, Siddhartha
    Xie, Hao
    Bin-Riaz, Irbaz
    Sharma, Prabin
    Durani, Urshila
    Goyal, Gaurav
    Borah, Bijan
    Borad, Mitesh J.
    Smoot, Rory L.
    Roberts, Lewis R.
    Go, Ronald S.
    McWilliams, Robert R.
    Mahipal, Amit
    EJSO, 2019, 45 (08): : 1432 - 1438
  • [6] Chemotherapy with gemcitabine in intrahepatic cholangiocarcinoma: a retrospective analysis of nine patients
    Passek, F
    Eckert, R
    Cordes, A
    Maier, KP
    ANNALS OF ONCOLOGY, 2005, 16 : 324 - 325
  • [7] Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?
    Altman, Ariella M.
    Kizy, Scott
    Marmor, Schelomo
    Hui, Jane Y. C.
    Tuttle, Todd M.
    Jensen, Eric H.
    Denbo, Jason W.
    HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (05) : 577 - +
  • [8] ADJUVANT CHEMOTHERAPY FOR INTRAHEPATIC CHOLANGIOCARCINOMA: APPROACHING CLINICAL PRACTICE CONSENSUS?
    Altman, Ariella M.
    Kizy, Scott
    Marmor, Schelomo
    Sheka, Adam
    Yuet, Jane
    Hui, Ching
    Tuttle, Todd
    Jensen, Eric H.
    Denbo, Jason W.
    GASTROENTEROLOGY, 2018, 154 (06) : S1332 - S1332
  • [9] Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus
    Qu, Wei-Feng
    Liu, Wei-Ren
    Shi, Ying-Hong
    HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10 (06) : 887 - 889
  • [10] Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy
    Endo, Yutaka
    Moazzam, Zorays
    Alaimo, Laura
    Lima, Henrique A.
    Munir, Muhammad M.
    Shaikh, Chanza F.
    Guglielmi, Alfredo
    Aldrighetti, Luca
    Weiss, Matthew
    Bauer, Todd W.
    Alexandrescu, Sorin
    Poultsides, George A.
    Kitago, Minoru
    Maithel, Shishir K.
    Marques, Hugo P.
    Martel, Guillaume
    Pulitano, Carlo
    Shen, Feng
    Cauchy, Francois
    Koerkamp, Bas G.
    Endo, Itaru
    Pawlik, Timothy M.
    HPB, 2023, 25 (02) : 229 - 238